Trump administration advances plan for peptide drugs favored by RFK Jr.
HHS sent an interim compounding policy for certain peptides to the White House for review; no rule or access change has been issued.
TL;DR
- HHS submitted an interim policy concerning pharmacy compounding of certain peptides for White House review.
- The Associated Press and The Epoch Times reported that the submission appeared in the federal review tracker; AP cited people familiar with a possible temporary enforcement-discretion approach.
- The policy text has not been published and no final decision has been made, so current authorization or evidence of safety and efficacy has not changed.
The U.S. Department of Health and Human Services submitted an “Interim Access Policy” concerning compounding of certain peptides to the White House Office of Management and Budget. The Associated Press and The Epoch Times reported that the submission appeared in the federal regulatory review tracker on October 14. [1] [2]
AP cited two people familiar with the plan who said it may include temporary enforcement discretion for compounding some peptides. The Epoch Times reported the title of the tracker entry but said the detailed policy text was not public. [1] [2]
Submission for review is an early administrative step, not FDA approval or a final rule. The available public record does not establish which substances would be covered or what conditions would apply. [1] [2]
This is a policy review concerning compounding and enforcement, rather than new clinical evidence about peptide therapies. Whether the proposal advances, which products it may cover and how safety concerns are addressed remain unresolved. [1] [2]
Why it matters
The development concerns a possible change in compounding policy, not a clinical finding. The proposal’s scope and final status are unknown, and no new evidence of safety or efficacy is reported.
Editor's note
Distinguishes the policy submission from FDA approval and from clinical evidence; detailed text remains unpublished.